• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.08%

    Northwest Biotherapeutics, Inc. (NWBO)

    -NasdaqCM
    9.82 Down 0.10(1.01%) Jul 2, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Northwest Biotherapeutics, Inc.
    4800 Montgomery Lane
    Suite 800
    Bethesda, MD 20814
    United States - Map
    Phone: 240-497-9024
    Website: http://www.nwbio.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:12

    Business Summary 

    Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. The company’s products include DCVax-L, which is under Phase III brain cancer trial for treating brain and ovarian cancer; DCVax-Direct that is under Phase I/II clinical trial for various types of inoperable solid tumor cancers; and DCVax-Prostate for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Northwest Biotherapeutics, Inc.

    Corporate Governance 
    Northwest Biotherapeutics, Inc.’s ISS Governance QuickScore as of Jun 1, 2015 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 7; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Ms. Linda F. Powers J.D., 60
    Chairperson, Chief Exec. Officer, Pres, Chief Financial Officer and Principal Accounting Officer
    500.00K0.00
    Dr. Alton L. Boynton Ph.D., 71
    Founder, Chief Scientific Officer, Sec. and Director
    325.00K0.00
    Dr. Marnix L. Bosch Ph.D., MBA, 55
    Chief Technical Officer
    425.00K0.00
    Mr. Leslie J. Goldman , 70
    Sr. VP of Bus. Devel.
    425.00K0.00
    Dr. Anthony E. Maida III, MA, MBA, Ph.D., 62
    Sr. VP of Clinical Research
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders